Bionaturis Group and the US-biotech company Allotropic Tech has signed an agreement to work together in the development of biological products for pharmaceutical, petrochemical, nutritional, and cosmetic industries, among others. Allotropic Tech’s personnel are pioneers in the field of expression systems in insects such as FLYLIFE. 

According to Bionaturis Group’s CEO, Victor Infante, “with this agreement, Bionaturis Group continues adding up strategic alliances and improving its competitiveness. Allotropic’s team is composed of recognized experts at using insects to express difficult to obtain proteins, and therefore, one more value added for our clients and development partners. This agreement will also allow us to broaden our product portfolio”.

Allotropic’s CEO, Robert Balcerzak, has stated “we look forward to collaborating with Bionaturis in advancing the expression of proteins in insects and are particularly excited about drawing on Bionaturis’ worldwide sales presence”.

About Allotropic

Allotropic Tech is located in Baltimore MD USA with facilities located in the mid-Atlantic corridor region. Allotropic Tech has extensive experience supplying recombinant proteins with particular emphasis on supplying proteins to government laboratories, university research departments and corporate R&D departments.

About Bionaturis

The Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in the vaccines research, the biotechnological Group which envisages a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).